南华生物医药股份有限公司 证券代码：000504 证券简称：*ST 生物 公告编号：2025-058 关于挂牌出售控股子公司股权的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 特别提示： 南华生物医药股份有限公司（以下简称"公司"）于2025年6月18日召开了 第十一届董事会第二十八次会议，审议通过了《关于授权经营层挂牌出售子公司 股权的议案》，拟通过湖南省联合产权交易所（以下简称"湖南联交所"）公开 挂牌出售持有的南华和平医院管理（湖南）有限公司（以下简称"南华和平"） 全部股权；并于2025年8月21日披露《关于挂牌出售控股子公司股权的进展公告》。 相关详情请见公司于2025年6月19日和2025年8月21日在巨潮资讯网披露的公告 （公告编号：2025-031、2025-049）。 公司近日收到湖南联交所出具的《网络竞价结果通知书》（待定受让方）， 确认一名待定受让方，最高报价为1,999.19万元。目前已进入原股东征询环节， 若南华和平原股东放弃行使优先购买权，则最高报价方成为受让方；若南华和平 原股东行使优先购买权，则原股东成为受让方，成交价 ...

Core Viewpoint - Nanhua Biomedical Co., Ltd. has approved the sale of its subsidiary Nanhua Heping Hospital Management (Hunan) Co., Ltd. with a highest bid of 19.9919 million yuan [1] Group 1 - The board of Nanhua Biomedical approved the proposal to sell the entire equity of its subsidiary [1] - The highest bid received for the subsidiary is 19.9919 million yuan, which is also the listing price [1] - The process is currently in the stage of soliciting opinions from original shareholders, who have the right of first refusal [1] Group 2 - If the original shareholders waive their right, the highest bidder will become the acquirer; otherwise, the original shareholders will retain ownership [1] - This transaction does not constitute a related party transaction or a major asset restructuring [1] - The company will disclose further developments in a timely manner and remind investors to pay attention to risks [1]

Core Viewpoint - The company, Nanhua Biopharmaceutical Co., Ltd., is participating in an online investor reception day and semi-annual performance briefing to enhance communication with investors [1]. Group 1 - The event is organized by the Hunan Securities Regulatory Bureau, Hunan Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [1] - The online event will take place on September 19, 2025, from 14:00 to 17:00 [1]. - Company executives will discuss the company's performance for the first half of 2024 to 2025, governance, development strategy, operational status, and sustainable development [1]. Group 2 - Investors can participate through the "Panorama Roadshow" website, WeChat public account, or by downloading the Panorama Roadshow APP [1]. - The company encourages active participation from investors during the event [1].

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，南华生物医药股份有限公司（以下简称 "公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公 司联合举办的"资本聚三湘楚光耀新程——2025 年湖南辖区上市公司投资者网 上集体接待日暨半年度业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:00-17:00。届 时公司高管将在线就公司 2024 年至 2025 半年度业绩、公司治理、发展战略、经 营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 证券代码：000504 证券简称：*ST 生物 公告编号：2025-057 南华生物医药股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日暨半 年度业绩说明会活动的公告 南华生物 ...

证券代码：000504 证券简称：*ST 生物 公告编号：2025-056 南华生物医药股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 重要提示： 1、南华生物医药股份有限公司（以下简称"公司"或"南华生物"）于2025 年8月12日披露了《关于筹划重大资产重组暨签署股权收购意向协议的提示性公 告》（公告编号：2025-047），公司筹划以现金方式收购湖南慧泽生物医药科技 有限公司（以下简称"慧泽医药"或"标的公司"）51%股权，本次交易完成后， 慧泽医药将成为公司控股子公司并纳入合并报表范围。 2、截至本公告披露日，本次重大资产重组工作正在进行，相关尽职调查、 审计、评估等各项工作正在推进中。交易相关方就本次收购事项正在持续沟通协 调中，目前尚未签署正式协议。后续公司将按照《上市公司重大资产重组管理办 法》等相关规定履行相应的审批程序和信息披露义务。本次交易尚处于筹划阶段， 相关事项尚存在不确定性。敬请广大投资者谨慎决策，注意投资风险。 一、本次交易概述 2025年8月11日，公司与程泽能、易木林、长沙君合致远 ...

Group 1 - The company plans to acquire a 43.05% stake in Loudi Jinhong New Materials Co., Ltd. for 48.6249 million yuan and will also increase its capital by 30 million yuan [1][2] - After the acquisition, the company will hold a 55.00% stake in Loudi Jinhong New Materials Co., Ltd., which will be included in the company's consolidated financial statements [1] - The board meeting was held on September 5, 2025, with all 7 participating directors voting in favor of the acquisition proposal [2] Group 2 - The proposal will be submitted to the shareholders' meeting for approval, and the management team is authorized to handle the acquisition procedures [2] - A temporary shareholders' meeting is scheduled for September 22, 2025, to review the proposal for the capital increase [2]

Meeting Information - The company, Nanhua Biopharmaceutical Co., Ltd., has announced the convening of the 2025 Third Extraordinary General Meeting of Shareholders on September 22, 2025, from 9:15 to 15:00 [1][2] - The meeting will allow both on-site and online voting, with the online voting available through the Shenzhen Stock Exchange trading system and internet voting system [1][4] Shareholder Participation - All ordinary shareholders registered by the close of trading on the registration date are entitled to attend the meeting and vote, either in person or by proxy [2][3] - Proxies do not need to be shareholders of the company, and a template for the authorization letter is provided [2] Agenda Items - The main proposal for the meeting is to plan a cash acquisition of equity in Loudi Jinhong New Materials Co., Ltd. and to increase capital [2] - This proposal requires a special resolution, needing more than two-thirds of the voting rights held by attending shareholders to pass [2][3] Voting Procedures - Votes will be counted separately for small and medium investors, excluding directors, senior management, and major shareholders [3] - The voting process includes options for agreeing, opposing, or abstaining for non-cumulative voting proposals [6] Documentation and Contact Information - Relevant documents, including resolutions from the board meetings, will be available for review [5] - Contact details for inquiries include phone and email information for the company [4][5]

Group 1 - The company plans to acquire a 43.05% stake in Loudi Jinhong New Materials Co., Ltd. for 48.6249 million yuan and will also increase its capital by 30 million yuan, resulting in a total investment of 78.6249 million yuan [1][2][8] - After the acquisition and capital increase, the company will hold a 55% stake in the target company, gaining control and consolidating it into its financial statements [1][2][8] - The target company's valuation is set at 113.1297 million yuan, with the acquisition price being slightly lower at 112.9539 million yuan [2][7] Group 2 - The target company, Loudi Jinhong New Materials Co., Ltd., specializes in the recycling and reuse of waste power batteries, particularly in the new energy sector [4][5] - The company aims to extend its business into the circular economy sector, aligning with national policies and market demands for battery recycling [12][13] - The acquisition is expected to enhance the company's revenue and profit margins while optimizing its business structure [12][13] Group 3 - The transaction will be financed entirely through the company's own funds, with sufficient liquidity available for the payment [13] - The target company has a stable customer base and holds qualifications that provide tax incentives, which will help reduce operational costs [12][13] - The company has set performance commitments for the target company, including annual revenue targets of no less than 250 million yuan from the acquisition date until the end of 2028 [10][11]

Core Viewpoint - Nanhua Biological Medicine Co., Ltd. intends to acquire the equity of Loudi Jinhong New Materials Co., Ltd., and an asset valuation report has been prepared to reflect the market value of the total equity of the target company as of the valuation benchmark date of July 31, 2025 [3][4][19]. Group 1: Valuation Purpose and Scope - The purpose of the valuation is to provide a fair reflection of the market value of the total equity of Loudi Jinhong New Materials Co., Ltd. involved in the acquisition by Nanhua Biological Medicine Co., Ltd. [3][14]. - The valuation scope includes all audited assets and related liabilities of Loudi Jinhong New Materials Co., Ltd. as of the valuation benchmark date [4][15]. Group 2: Financial Overview of the Target Company - The total book assets of Loudi Jinhong New Materials Co., Ltd. amount to 200.45 million yuan, with current assets of 42.58 million yuan and non-current assets of 157.87 million yuan [4][15]. - The total liabilities are 113.56 million yuan, consisting of current liabilities of 40.33 million yuan and non-current liabilities of 73.33 million yuan [4][15]. - The net assets are valued at 86.89 million yuan [4][15]. Group 3: Valuation Results - The valuation report indicates that the assessed value of the total assets is 226.69 million yuan, resulting in an increase of 26.24 million yuan, representing a growth rate of 13.09% [4][19]. - The assessed value of the net assets is 113.13 million yuan, with an increase of 26.24 million yuan, reflecting a growth rate of 30.20% [4][19]. Group 4: Valuation Methodology - The valuation methods employed include the asset-based approach and the market approach, with the asset-based approach yielding the final valuation results [4][19]. - The asset-based approach assesses the value based on the balance sheet of the target company, considering both on-balance and identifiable off-balance sheet assets and liabilities [19][24].

Group 1 - The core point of the article is that *ST Bio (SZ 000504) held its 12th third board meeting on September 5, 2025, to discuss the proposal for the third temporary shareholders' meeting of 2025 [1] - For the first half of 2025, *ST Bio's revenue composition was as follows: stem cell industry accounted for 83.88%, energy-saving technology services accounted for 15.87%, and other businesses accounted for 0.25% [1] - As of the time of reporting, *ST Bio's market capitalization was 3.2 billion yuan [1] Group 2 - The article also mentions that Haidilao is diversifying into various businesses, including opening a bakery by West Lake and entering the high-end hotel sector, but the survival rate of its sub-brands is less than 50% [1]